Published summary: 2026-03-07
Where the evidence converges
Meta-analysis of 18 trials shows CB1 receptor blockers consistently caused diarrhea and GI symptoms, suggesting potential repurposing for constipation-predominant IBS if psychiatric side effects can be avoided
Strong evidence · 4 studies
The trials analyzed were designed for obesity/metabolic conditions, not IBS. GI adverse events were secondary outcomes, not primary endpoints. Psychiatric side effects (which led to rimonabant's withd
Meta-analysis of 13 clinical studies found CBD and THC had trivial, non-significant effects on blood inflammatory markers (IL-6, IL-8, IL-10, TNF-alpha), with evidence certainty ranging from very low to moderate
Strong evidence · 4 studies
Only 13 studies met inclusion criteria with small sample sizes per meta-analysis, heterogeneous populations and dosing regimens, circulating biomarkers may not reflect tissue-level inflammation, GRADE
Meta-analysis of 46 studies finds cannabis use elevates both pro- and anti-inflammatory markers, suggesting immunomodulation rather than anti-inflammatory effects
Strong evidence · 4 studies
Most evidence from cross-sectional studies. Only 2 prospective and 10 RCTs. Heterogeneity in cannabinoid type, dose, and duration across studies.
Where questions remain
THC suppressed macrophages, T cells, and NK cells and reduced infection resistance in labs and animals, but direct evidence of increased infections in human marijuana users was unavailable
Moderate evidence · 41 studies
The review acknowledged that definitive human data was unavailable. Animal and in vitro models use different doses, routes, and exposure durations than human cannabis use. The THC concentrations used
A 25-year research review found cannabinoids modulated all major immune cell types and altered resistance to multiple infections, while noting the endocannabinoid system's role in immune regulation needed further study
Moderate evidence · 41 studies
Narrative review format. The diversity of experimental models, doses, and endpoints across 25 years of research makes synthesis challenging. The translation from lab findings to human health risk rema
A review by THC discoverer Raphael Mechoulam tracing cannabinoids from ancient use to modern clinical applications in nausea, appetite, multiple sclerosis, arthritis, and neuroprotection
Moderate evidence · 41 studies
As a broad overview by a single researcher, this paper provided perspective rather than systematic analysis. The review covered many therapeutic areas briefly rather than deeply. Some of the promising
Review documenting that cannabis and other drugs of abuse suppress immune function through receptor-mediated mechanisms, increasing infection susceptibility, with implications for HIV/AIDS
Moderate evidence · 41 studies
The review covered five different drug classes broadly, limiting depth on cannabis specifically. Much of the evidence was from in vitro and animal studies. The clinical significance of cannabinoid imm
Research gaps
- Only 13 randomized controlled trials exist out of 370 studies — most evidence is observational or from reviews.
- 60% of studies provide only preliminary evidence. Higher-quality research designs are needed.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Large meta-analysis finds regular cannabis use raises both pro-inflammatory and anti-inflammatory markers, not just one or the other
Cannabis is widely described as "anti-inflammatory," but this meta-analysis shows regular use modulates the immune system in both directions simultaneously, with implications for people using cannabis to manage inflammatory conditions.
Meta-Analysis Found CBD and THC Had Trivial Effects on Blood Inflammation Markers
CBD and THC are widely marketed as anti-inflammatory, often based on preclinical data. This meta-analysis of actual human clinical trials shows that the anti-inflammatory effects observed in cells and animals have not consistently translated to measurable changes in human blood markers.
CB1 receptor blockers caused diarrhea so consistently they might actually treat constipation-dominant IBS
IBS with constipation has limited treatment options. This creative approach of repurposing a known side effect (diarrhea from CB1 blockers) into a therapeutic benefit illustrates how understanding the endocannabinoid system's role in gut function could yield new treatments.
About 20% of rheumatology patients actively use cannabis, and meta-analysis shows pain improvement
Cannabis use is common among rheumatology patients and often undisclosed. Clinicians should proactively ask about cannabis use and understand the available evidence on pain effects to guide clinical conversations.
Meta-analysis finds extremely limited evidence for marijuana in Crohn's disease or ulcerative colitis
Despite widespread patient use of marijuana for IBD, this meta-analysis reveals that the controlled trial evidence base is almost nonexistent, with only 71 total patients across all eligible trials.
Cannabis Produced Clinical Response in 10 of 11 Crohn's Disease Patients Who Had Failed All Other Treatments
This was the first placebo-controlled trial of cannabis for Crohn's disease. The patients had failed all available treatments, making any clinical benefit significant. The 90% clinical response rate, combined with steroid weaning and symptom improvement, suggests cannabis may have genuine therapeuti
How the research developed
Pre-2000
7 studies published. Predominantly observational and review studies.
2000–2009
28 studies published. Includes 1 strong-evidence studies.
2010–2014
32 studies published. Includes 2 RCTs, 1 strong-evidence studies.
2015–2019
74 studies published. Includes 1 meta-analyses, 1 RCTs, 4 strong-evidence studies.
2020–present
229 studies published. Includes 4 meta-analyses, 10 RCTs, 3 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 370 peer-reviewed studies: 5 meta-analyses (1%), 13 randomized controlled trials (4%), 61 observational studies (16%), 118 reviews (32%), 3 case studies (1%), 170 other study types (46%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.